| Literature DB >> 32503815 |
Karel Smetana1,2, Jan Brábek3,4.
Abstract
COVID-19 is viral respiratory infection with frequently fatal lung complications in the elderly or in people with serious comorbidities. Lung destruction appears to be associated with a cytokine storm related to an increased level of interleukin-6 (IL6). Therapeutic targeting of the interleukin-6 signaling pathway can attenuate such a cytokine storm and can be beneficial for patients with COVID-19 in danger of pulmonary failure. This article demonstrates the importance of IL6 in progression of disease and the possibility of inhibition of IL6 signaling in COVID-19 therapy. CopyrightEntities:
Keywords: COVID-19 therapy; IL6; SARS-CoV-2; cytokine storm; lung failure; review
Mesh:
Substances:
Year: 2020 PMID: 32503815 DOI: 10.21873/invivo.11947
Source DB: PubMed Journal: In Vivo ISSN: 0258-851X Impact factor: 2.155